143 related articles for article (PubMed ID: 25211092)
1. Intralesional rituximab for primary iris lymphoma.
Demirci H; Grant JS; Elner VM
JAMA Ophthalmol; 2015 Jan; 133(1):104-5. PubMed ID: 25211092
[No Abstract] [Full Text] [Related]
2. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
[TBL] [Abstract][Full Text] [Related]
3. Contemplating the Diagnostic Certainty of Primary Iris Mucosa-Associated Lymphoid Tissue Lymphoma.
Margo CE
JAMA Ophthalmol; 2015 Aug; 133(8):969-70. PubMed ID: 25950116
[No Abstract] [Full Text] [Related]
4. Contemplating the Diagnostic Certainty of Primary Iris Mucosa-Associated Lymphoid Tissue Lymphoma—Reply.
Demirci H; Elner VM
JAMA Ophthalmol; 2015 Aug; 133(8):970. PubMed ID: 25950277
[No Abstract] [Full Text] [Related]
5. Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.
Bata BM; Pulido JS; Patel SV; Khan SP; Salomao D; Boyce TG; Bothun ED
J AAPOS; 2018 Apr; 22(2):159-161. PubMed ID: 29408337
[TBL] [Abstract][Full Text] [Related]
6. [Abdominal pain and rectorrhage in a 68-year-old woman].
Guardiola H; Pérez Muñoz N
Med Clin (Barc); 2005 Apr; 124(15):588-94. PubMed ID: 15860175
[No Abstract] [Full Text] [Related]
7. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma.
Seker M; Bilici A; Ustaalioglu BO; Salman T; Sonmez B; Canpolat NA; Salepci T; Gumus M; Yaylaci M
Leuk Res; 2009 Sep; 33(9):e154-6. PubMed ID: 19386361
[No Abstract] [Full Text] [Related]
8. Mantle cell lymphoma of the iris.
Economou MA; Kopp ED; All-Ericsson C; Seregard S
Acta Ophthalmol Scand; 2007 May; 85(3):341-3. PubMed ID: 17488468
[No Abstract] [Full Text] [Related]
9. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
[TBL] [Abstract][Full Text] [Related]
10. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
Duman BB; Sahin B; Ergin M; Guvenc B
Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
[TBL] [Abstract][Full Text] [Related]
11. Rituximab immunotherapy for ocular adnexal lymphoma: clinicopathologic correlation with 5-year follow-up.
Sokol JA; Landau L; Lauer SA
Ophthalmic Plast Reconstr Surg; 2009; 25(4):322-4. PubMed ID: 19617799
[TBL] [Abstract][Full Text] [Related]
12. Case report: Colonic MALT lymphoma.
Khan M; Chon D; Patil A
J Gastrointest Cancer; 2012 Dec; 43(4):622-5. PubMed ID: 22965352
[No Abstract] [Full Text] [Related]
13. Conjunctival and orbital lymphoma.
Shinder R
Ophthalmology; 2011 Aug; 118(8):1692; author reply 1692, 1692.e1. PubMed ID: 21813098
[No Abstract] [Full Text] [Related]
14. Acquired C1 esterase inhibitor deficiency in a marginal zone lymphoma patient treated with rituximab.
Ates O; Sunar V; Babacan T; Akin S; Kertmen N; Altundag K
J BUON; 2015; 20(1):349. PubMed ID: 25778339
[No Abstract] [Full Text] [Related]
15. Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.
Laurenti L; De Padua L; Battendieri R; Tarnani M; Sica S; Blasi MA; Savino G; Leone G
Leuk Res; 2011 May; 35(5):682-4. PubMed ID: 21334067
[TBL] [Abstract][Full Text] [Related]
16. Mucosa-associated lymphoid tissue (MALT) lymphoma presenting as subglottic stenosis: single-agent treatment using rituximab.
Bielinski C; Luu HS; Mau T
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):334-5. PubMed ID: 24334958
[No Abstract] [Full Text] [Related]
17. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma.
Stalika E; Kanellis G; Papalexandri A; Iskas M; Vrakidou E; Demonakou M; Anagnostopoulos A; Stamatopoulos K; Papadaki T
Leuk Lymphoma; 2014 Mar; 55(3):702-5. PubMed ID: 23725385
[No Abstract] [Full Text] [Related]
19. Recurrence of IgG4-related disease following treatment with rituximab.
Murakami J; Matsui S; Ishizawa S; Arita K; Wada A; Miyazono T; Hounoki H; Shinoda K; Taki H; Sugiyama T
Mod Rheumatol; 2013 Nov; 23(6):1226-30. PubMed ID: 22956241
[TBL] [Abstract][Full Text] [Related]
20. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
